Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Letermovir,Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Health Canada Approves PREVYMIS for CMV Disease Prevention in High-Risk Kidney Transplant
Details : Prevymis (letermovir) is a CMV DNA terminase complex inhibitor small molecule drug candidate, which is indicated for cytomegalovirus disease in high-risk adult kidney transplant recipients.
Brand Name : Prevymis
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 19, 2024
Lead Product(s) : Letermovir,Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex, which is indicated for the treatment of Cytomegalovirus.
Brand Name : Prevymis
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 17, 2023
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex and FDA Approves New Indication forCytomegalovirus.
Brand Name : Prevymis
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2023
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Letermovir,Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex.
Brand Name : Prevymis
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 17, 2023
Lead Product(s) : Letermovir,Aciclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In analysis of studies, compared to controls, primary prophylaxis with PREVYMIS was associated at 100 days of follow-up after alloHCT with: 87% lower odds of CMV reactivation; 91% lower odds for clinically significant CMV infection, 69% lower odds of CMV...
Brand Name : Prevymis
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2022
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PREVYMIS is a first-in-class antiviral agent that was approved by the U.S. Food and Drug Administration in 2017 and is indicated for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem ce...
Brand Name : Prevymis
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2022
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Royalty Pharma
Deal Size : $220.0 million
Deal Type : Acquisition
Details : Prevymis™ (letermovir) was approved by the US FDA in 2017 and by the EMA and Japan’s PMDA in 2018 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant who are at high ri...
Brand Name : Prevymis
Molecule Type : Small molecule
Upfront Cash : $220.0 million
June 09, 2020
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Royalty Pharma
Deal Size : $220.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?